이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Novacyt 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Lyn Rees

최고 경영자

UK£336.1k

총 보상

CEO 급여 비율	31.0%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

CEO 보상 분석

Lyn Rees 의 보수는 Novacyt 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	UK£336k	UK£104k	-UK£28m

보상 대 시장: Lyn 의 총 보상 ($USD 427.66K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 683.56K ).

보상과 수익: Lyn 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Lyn Rees (51 yo)

less than a year

테뉴어

UK£336,106

보상

Mr. Lyn Dafydd Rees serves as Executive Director at Novacyt S. A. since September 2023 and serves as its Chief Executive Officer since May 01, 2024. He serves as Non-Executive Director at MyHealthChecked P...

리더십 팀

이름	위치	테뉴어	보상	소유권
Lyn Rees	CEO & Executive Director	less than a year	UK£336.11k	데이터 없음
Steve Gibson	CFO & Director	less than a year	데이터 없음	데이터 없음
Bryan Close	Chief Operations Officer	2.4yrs	데이터 없음	데이터 없음
Joanne Mason	Chief Scientific Officer & Director	less than a year	데이터 없음	데이터 없음
Mandy Cowling	Corporate & Investor Relations Manager	no data	데이터 없음	데이터 없음
David Franks	Chief Human Resources Officer	3.2yrs	데이터 없음	데이터 없음
Paul Oladimeji	Group Head of R&D	no data	데이터 없음	데이터 없음

0.4yrs

평균 재임 기간

경험이 풍부한 관리: NVYT.F 의 관리팀은 경험 (평균 재직 기간 0.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lyn Rees	CEO & Executive Director	less than a year	UK£336.11k	데이터 없음
Steve Gibson	CFO & Director	less than a year	데이터 없음	데이터 없음
Joanne Mason	Chief Scientific Officer & Director	less than a year	데이터 없음	데이터 없음
John Brown	Non-Executive Director	less than a year	UK£15.24k	데이터 없음
Juliet Thompson	Independent Non-Executive Director	7yrs	UK£48.93k	데이터 없음
Jean-Pierre Crinelli	Independent Non-Executive Director	no data	UK£34.04k	0.048% £ 20.2k
David Gardner	Member of Scientific Committee	no data	데이터 없음	데이터 없음
Marco Zonta	Member of Scientific Committee	no data	데이터 없음	데이터 없음
Isabelle Cartier	Member of Scientific Committee	no data	데이터 없음	데이터 없음
Geneviève Bourg-Heckly	Member of Scientific Committee	no data	데이터 없음	데이터 없음
James Wakefield	Independent Non-Executive Chairman of the Board	10.4yrs	UK£120.00k	0.062% £ 26.1k

0.8yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: NVYT.F 의 이사회는 경험(평균 재직 기간 0.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Novacyt 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Novacyt S.A., Annual General Meeting, Jun 26, 2024

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Recent updates

Novacyt S.A., Annual General Meeting, Jun 26, 2024

Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024

Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Novacyt S.A. (ENXTPA:ALNOV) acquired IT-IS International Ltd. for £12 million.

Novacyt Signs a New Supply Contract with the UK Department of Health and Social Care

Novacyt S.A. Announces Launch of COVID-19 Antibody Test

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령